Do analysts prefer AYTU or NCNA?

Aytu BioPharma presently has a consensus price target of $10.75, suggesting a potential upside of 377.78%. Given Aytu BioPharma's stronger consensus rating and higher probable upside, equities research analysts plainly believe Aytu BioPharma is more favorable than NuCana. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aytu BioPharma 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 NuCana 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is AYTU or NCNA more profitable?

NuCana has a net margin of 0.00% compared to Aytu BioPharma's net margin of -60.17%. NuCana's return on equity of -41.90% beat Aytu BioPharma's return on equity. Company Net Margins Return on Equity Return on Assets Aytu BioPharma -60.17% -69.93% -13.25% NuCana N/A -41.90% -33.69%

Do analysts recommend NCNA or PLRZ?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NuCana 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Polyrizon 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, NCNA or PLRZ?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NuCana N/A N/A -$38.71M -$3.81 N/A Polyrizon N/A N/A -$3.34M N/A N/A

Is NCNA or PLRZ more profitable?

Polyrizon's return on equity of 0.00% beat NuCana's return on equity. Company Net Margins Return on Equity Return on Assets NuCana N/A -41.90% -33.69% Polyrizon N/A N/A N/A

Do analysts rate NCNA or CLRB?

Cellectar Biosciences has a consensus price target of $11.00, indicating a potential upside of 334.78%. Given Cellectar Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Cellectar Biosciences is more favorable than NuCana. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NuCana 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cellectar Biosciences 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80

Which has preferable valuation and earnings, NCNA or CLRB?

Cellectar Biosciences is trading at a lower price-to-earnings ratio than NuCana, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NuCana N/A N/A -$38.71M -$3.81 N/A Cellectar Biosciences N/A N/A -$21.79M -$3.84 N/A

Is NCNA or CLRB more profitable?

NuCana's return on equity of -41.90% beat Cellectar Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets NuCana N/A -41.90% -33.69% Cellectar Biosciences N/A -185.35% -115.42%

Do analysts prefer TVRD or NCNA?

Tvardi Therapeutics presently has a consensus price target of $18.00, suggesting a potential upside of 889.01%. Given Tvardi Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Tvardi Therapeutics is more favorable than NuCana. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tvardi Therapeutics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.78 NuCana 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is TVRD or NCNA more profitable?

NuCana's return on equity of -41.90% beat Tvardi Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Tvardi Therapeutics N/A -145.40% -91.11% NuCana N/A -41.90% -33.69%

Do analysts rate NCNA or BFRI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NuCana 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Biofrontera 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher valuation & earnings, NCNA or BFRI?

Biofrontera has higher revenue and earnings than NuCana. Biofrontera is trading at a lower price-to-earnings ratio than NuCana, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NuCana N/A N/A -$38.71M -$3.81 N/A Biofrontera $46.18M 0.51 -$10.54M -$0.45 N/A

Is NCNA or BFRI more profitable?

NuCana has a net margin of 0.00% compared to Biofrontera's net margin of -13.78%. NuCana's return on equity of -41.90% beat Biofrontera's return on equity. Company Net Margins Return on Equity Return on Assets NuCana N/A -41.90% -33.69% Biofrontera -13.78% -145.81% -31.30%

NuCana (NCNA) Competitors

$1.76 0.00 (0.00%)

As of 08/28/2026 04:00 PM Eastern

Compare

NCNA vs. AYTU, PLRZ, CLRB, TVRD, and BFRI

Should you buy NuCana stock or one of its competitors? NuCana's main competitors and comparable companies include Aytu BioPharma (AYTU), Polyrizon (PLRZ), Cellectar Biosciences (CLRB), Tvardi Therapeutics (TVRD), and Biofrontera (BFRI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does NuCana compare to Aytu BioPharma?

Aytu BioPharma (NASDAQ:AYTU) and NuCana (NASDAQ:NCNA) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends, media sentiment and valuation.

33.5% of Aytu BioPharma shares are owned by institutional investors. Comparatively, 44.0% of NuCana shares are owned by institutional investors. 4.9% of Aytu BioPharma shares are owned by company insiders. Comparatively, 31.2% of NuCana shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Aytu BioPharma and Aytu BioPharma both had 1 articles in the media. Aytu BioPharma's average media sentiment score of 1.89 equaled NuCana'saverage media sentiment score.

Company	Overall Sentiment
Aytu BioPharma	Very Positive
NuCana	Very Positive

Aytu BioPharma has higher revenue and earnings than NuCana. Aytu BioPharma is trading at a lower price-to-earnings ratio than NuCana, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aytu BioPharma	$66.38M	0.36	-$13.56M	-$4.58	N/A
NuCana	N/A	N/A	-$38.71M	-$3.81	N/A

Aytu BioPharma presently has a consensus price target of $10.75, suggesting a potential upside of 377.78%. Given Aytu BioPharma's stronger consensus rating and higher probable upside, equities research analysts plainly believe Aytu BioPharma is more favorable than NuCana.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aytu BioPharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
NuCana	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

NuCana has a net margin of 0.00% compared to Aytu BioPharma's net margin of -60.17%. NuCana's return on equity of -41.90% beat Aytu BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aytu BioPharma	-60.17%	-69.93%	-13.25%
NuCana	N/A	-41.90%	-33.69%

Aytu BioPharma has a beta of 0.25, suggesting that its share price is 75% less volatile than the broader market. Comparatively, NuCana has a beta of 2.25, suggesting that its share price is 125% more volatile than the broader market.

Summary

NuCana beats Aytu BioPharma on 7 of the 13 factors compared between the two stocks.

How does NuCana compare to Polyrizon?

NuCana (NASDAQ:NCNA) and Polyrizon (NASDAQ:PLRZ) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, media sentiment, analyst recommendations, institutional ownership and risk.

Polyrizon's return on equity of 0.00% beat NuCana's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NuCana	N/A	-41.90%	-33.69%
Polyrizon	N/A	N/A	N/A

In the previous week, Polyrizon had 1 more articles in the media than NuCana. MarketBeat recorded 2 mentions for Polyrizon and 1 mentions for NuCana. NuCana's average media sentiment score of 1.89 beat Polyrizon's score of 0.43 indicating that NuCana is being referred to more favorably in the media.

Company	Overall Sentiment
NuCana	Very Positive
Polyrizon	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NuCana	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Polyrizon	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

NuCana has a beta of 2.25, meaning that its share price is 125% more volatile than the broader market. Comparatively, Polyrizon has a beta of -1.5, meaning that its share price is 250% less volatile than the broader market.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NuCana	N/A	N/A	-$38.71M	-$3.81	N/A
Polyrizon	N/A	N/A	-$3.34M	N/A	N/A

44.0% of NuCana shares are owned by institutional investors. 31.2% of NuCana shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

NuCana and Polyrizon tied by winning 4 of the 8 factors compared between the two stocks.

How does NuCana compare to Cellectar Biosciences?

NuCana (NASDAQ:NCNA) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, media sentiment, risk, earnings and profitability.

44.0% of NuCana shares are held by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are held by institutional investors. 31.2% of NuCana shares are held by company insiders. Comparatively, 2.6% of Cellectar Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Cellectar Biosciences is trading at a lower price-to-earnings ratio than NuCana, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NuCana	N/A	N/A	-$38.71M	-$3.81	N/A
Cellectar Biosciences	N/A	N/A	-$21.79M	-$3.84	N/A

NuCana has a beta of 2.25, indicating that its stock price is 125% more volatile than the broader market. Comparatively, Cellectar Biosciences has a beta of 0.55, indicating that its stock price is 45% less volatile than the broader market.

Cellectar Biosciences has a consensus price target of $11.00, indicating a potential upside of 334.78%. Given Cellectar Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Cellectar Biosciences is more favorable than NuCana.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NuCana	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

NuCana's return on equity of -41.90% beat Cellectar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NuCana	N/A	-41.90%	-33.69%
Cellectar Biosciences	N/A	-185.35%	-115.42%

In the previous week, Cellectar Biosciences had 1 more articles in the media than NuCana. MarketBeat recorded 2 mentions for Cellectar Biosciences and 1 mentions for NuCana. NuCana's average media sentiment score of 1.89 beat Cellectar Biosciences' score of 0.93 indicating that NuCana is being referred to more favorably in the media.

Company	Overall Sentiment
NuCana	Very Positive
Cellectar Biosciences	Positive

Summary

NuCana beats Cellectar Biosciences on 8 of the 14 factors compared between the two stocks.

How does NuCana compare to Tvardi Therapeutics?

Tvardi Therapeutics (NASDAQ:TVRD) and NuCana (NASDAQ:NCNA) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, media sentiment, dividends, analyst recommendations and profitability.

Tvardi Therapeutics has higher revenue and earnings than NuCana. Tvardi Therapeutics is trading at a lower price-to-earnings ratio than NuCana, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tvardi Therapeutics	$7.14M	3.40	-$18.21M	-$2.79	N/A
NuCana	N/A	N/A	-$38.71M	-$3.81	N/A

44.7% of Tvardi Therapeutics shares are held by institutional investors. Comparatively, 44.0% of NuCana shares are held by institutional investors. 7.4% of Tvardi Therapeutics shares are held by company insiders. Comparatively, 31.2% of NuCana shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Tvardi Therapeutics has a beta of 0.39, meaning that its share price is 61% less volatile than the broader market. Comparatively, NuCana has a beta of 2.25, meaning that its share price is 125% more volatile than the broader market.

In the previous week, Tvardi Therapeutics had 3 more articles in the media than NuCana. MarketBeat recorded 4 mentions for Tvardi Therapeutics and 1 mentions for NuCana. NuCana's average media sentiment score of 1.89 beat Tvardi Therapeutics' score of 0.64 indicating that NuCana is being referred to more favorably in the news media.

Company	Overall Sentiment
Tvardi Therapeutics	Positive
NuCana	Very Positive

NuCana's return on equity of -41.90% beat Tvardi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tvardi Therapeutics	N/A	-145.40%	-91.11%
NuCana	N/A	-41.90%	-33.69%

Tvardi Therapeutics presently has a consensus price target of $18.00, suggesting a potential upside of 889.01%. Given Tvardi Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Tvardi Therapeutics is more favorable than NuCana.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tvardi Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
NuCana	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Tvardi Therapeutics beats NuCana on 9 of the 15 factors compared between the two stocks.

How does NuCana compare to Biofrontera?

NuCana (NASDAQ:NCNA) and Biofrontera (NASDAQ:BFRI) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations and risk.

NuCana has a net margin of 0.00% compared to Biofrontera's net margin of -13.78%. NuCana's return on equity of -41.90% beat Biofrontera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NuCana	N/A	-41.90%	-33.69%
Biofrontera	-13.78%	-145.81%	-31.30%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NuCana	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Biofrontera	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Biofrontera has higher revenue and earnings than NuCana. Biofrontera is trading at a lower price-to-earnings ratio than NuCana, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NuCana	N/A	N/A	-$38.71M	-$3.81	N/A
Biofrontera	$46.18M	0.51	-$10.54M	-$0.45	N/A

44.0% of NuCana shares are held by institutional investors. Comparatively, 10.1% of Biofrontera shares are held by institutional investors. 31.2% of NuCana shares are held by insiders. Comparatively, 8.1% of Biofrontera shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

NuCana has a beta of 2.25, indicating that its stock price is 125% more volatile than the broader market. Comparatively, Biofrontera has a beta of 0.78, indicating that its stock price is 22% less volatile than the broader market.

In the previous week, Biofrontera had 1 more articles in the media than NuCana. MarketBeat recorded 2 mentions for Biofrontera and 1 mentions for NuCana. NuCana's average media sentiment score of 1.89 beat Biofrontera's score of 1.44 indicating that NuCana is being referred to more favorably in the media.

Company	Overall Sentiment
NuCana	Very Positive
Biofrontera	Positive

Summary

NuCana and Biofrontera tied by winning 7 of the 14 factors compared between the two stocks.

Get NuCana News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NCNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NCNA vs. The Competition

Export

Metric	NuCana	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$7.32M	$12.11B	$7.18B	$12.89B
Dividend Yield	N/A	2.62%	2.54%	11.28%
P/E Ratio	-0.46	787.65	273.17	25.45
Price / Sales	N/A	759.94	638.19	104.21
Price / Cash	N/A	15.32	28.74	36.03
Price / Book	0.23	10.49	11.08	6.36
Net Income	-$38.71M	$2.83B	$3.48B	$349.79M
7 Day Performance	19.73%	0.58%	0.38%	-0.40%
1 Month Performance	33.33%	5.69%	7.89%	4.24%
1 Year Performance	-44.83%	6.19%	24.71%	15.13%

NuCana Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NCNA NuCana	1.3897 of 5 stars	$1.76 flat	N/A	-44.8%	$7.32M	N/A	N/A	30	High Trading Volume
AYTU Aytu BioPharma	2.9825 of 5 stars	$2.24 -2.6%	$10.75 +379.9%	-4.3%	$24.69M	$66.38M	N/A	160	Positive News
PLRZ Polyrizon	0.2699 of 5 stars	$12.80 +9.8%	N/A	+101.1%	$24.30M	N/A	N/A	N/A	Short Interest Increase Gap Down
CLRB Cellectar Biosciences	2.7127 of 5 stars	$2.54 flat	$11.00 +333.1%	-48.0%	$24.01M	N/A	N/A	10
TVRD Tvardi Therapeutics	3.7769 of 5 stars	$1.80 +1.1%	$18.00 +900.0%	-93.9%	$23.74M	$7.14M	N/A	80	News Coverage Analyst Downgrade Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NCNA) was last updated on 8/31/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NuCana (NCNA) Competitors

NCNA vs. AYTU, PLRZ, CLRB, TVRD, and BFRI

How does NuCana compare to Aytu BioPharma?

Summary

How does NuCana compare to Polyrizon?

Summary

How does NuCana compare to Cellectar Biosciences?

Summary

How does NuCana compare to Tvardi Therapeutics?

Summary

How does NuCana compare to Biofrontera?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NCNA vs. The Competition

NuCana Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NuCana (NCNA) Competitors

NCNA vs. AYTU, PLRZ, CLRB, TVRD, and BFRI

How does NuCana compare to Aytu BioPharma?

Do insiders and institutionals hold more shares of AYTU or NCNA?

Does the media favor AYTU or NCNA?

Which has preferable earnings and valuation, AYTU or NCNA?

Do analysts prefer AYTU or NCNA?

Is AYTU or NCNA more profitable?

Which has more risk and volatility, AYTU or NCNA?

Summary

How does NuCana compare to Polyrizon?

Is NCNA or PLRZ more profitable?

Does the media prefer NCNA or PLRZ?

Do analysts recommend NCNA or PLRZ?

Which has more risk & volatility, NCNA or PLRZ?

Which has preferable earnings & valuation, NCNA or PLRZ?

Do institutionals & insiders have more ownership in NCNA or PLRZ?

Summary

How does NuCana compare to Cellectar Biosciences?

Do institutionals and insiders have more ownership in NCNA or CLRB?

Which has preferable valuation and earnings, NCNA or CLRB?

Which has more volatility and risk, NCNA or CLRB?

Do analysts rate NCNA or CLRB?

Is NCNA or CLRB more profitable?

Does the media refer more to NCNA or CLRB?

Summary

How does NuCana compare to Tvardi Therapeutics?

Which has preferable valuation and earnings, TVRD or NCNA?

Do insiders & institutionals believe in TVRD or NCNA?

Which has more risk & volatility, TVRD or NCNA?

Does the media favor TVRD or NCNA?

Is TVRD or NCNA more profitable?

Do analysts prefer TVRD or NCNA?

Summary

How does NuCana compare to Biofrontera?

Is NCNA or BFRI more profitable?

Do analysts rate NCNA or BFRI?

Which has higher valuation & earnings, NCNA or BFRI?

Do insiders and institutionals believe in NCNA or BFRI?

Which has more risk & volatility, NCNA or BFRI?

Does the media refer more to NCNA or BFRI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NCNA vs. The Competition

NuCana Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools